Abstract
Despite improvements in the identification of causes of peripheral neuropathy, idiopathic polyneuropathy remains common. Medication and toxic neuropathy account for a small but important percentage of potentially preventable or reversible causes of neuropathy. New drugs that can induce neuropathy have been approved over the past several years, including the anticancer agents bortezomib, ixabepilone, and oxaliplatin. We review the neurotoxic effects of tumor necrosis factor-α blockers infliximab and etanercept, the inflammatory arthritis agent leflunomide, and the antibiotic linezolid. The controversy of statin-induced neuropathy continues to unfold; the large Fremantle Diabetes Study has suggested that statins may have neuroprotective effects. Dichloroacetate is a promising agent for lactic acidosis-associated disorders, but toxic neuropathy is a treatment-limiting factor. We also describe a progressive inflammatory neuropathy in swine slaughterhouse workers that appears to be a toxin-induced immune response.
References and Recommended Reading
Jain KK: Drug-induced peripheral neuropathies. In: Drug-Induced Neurological Disorders, edn 2. Edited by Jain KK. Seattle: Hogrefe & Huber; 2001:263–294.
Pratt RW, Weimer LH: Medication and toxin-induced peripheral neuropathy. Semin Neurol 2005, 25:204–216.
Chaudhry V, Chaudhry M, Crawford TO, et al.: Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337–340.
Graf WD, Chance PF, Lensch MW, et al.: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996, 77:1356–1362.
Prezant TR, Agapian JV, Bohlman MC, et al.: Mitochondrial ribosomal RNA mutation associated with both antibiotic induced and non-syndromic deafness. Nat Genet 1993; 4:289–294.
Weimer LH: Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2003, 3:86–92.
El-Cheikh J, Stoppa AM, Bouabdallah R, et al.: Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma 2008, 8:146–152.
Argyriou AA, Iconomou G, Kalofonos HP: Bortezomibinduced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593–1599.
Jackson G, Einsele H, Moreau P, Miguel JS: Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005, 3:591–602.
Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008, 6:455–467.
Bhushan S, Walko CM: Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer. Ann Pharmacother 2008, 42:1252–1261.
Cortes J, Baselga J: Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007, 12:271–280.
Roché H, Yelle L, Cognetti F, et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007, 25:3415–3420.
Thomas E, Tabernero J, Fornier M, et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399–3406.
Perez EA, Lerzo G, Pivot X, et al.: Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone analog, in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407–3414.
Denduluri N, Low JA, Lee JJ, et al.: Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007, 25:3421–3427.
Thomas E, Gomez HL, Li RK, et al.: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25:5210–5217.
Lehky TJ, Leonard GD, Wilson RH, et al.: Oxaliplat-ininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387–392.
Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055–4061.
Gamelin L, Boisdron-Celle M, Morel A, et al.: Oxaliplatin- related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008, 26:1188–1189.
Wolf S, Barton D, Kottschade L, et al.: Chemotherapyinduced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507–1515.
Stübgen JP: Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281–292.
Latov N, Sherman WH: Improvement with etanercept (Enbrel) in chronic inflammatory demyelinating polyneuropathy [abstract]. Ann Neurol 2000, 48:473.
Chin RL, Sherman WH, Sander HW, et al.: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003, 210:19–21.
Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44:1977–1983.
Shin IS, Baer AN, Kwon HJ, et al.: Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor antagonist therapy. Arthritis Rheum 2006, 54:1429–1434.
Richez C, Blanco P, Lagueny A, et al.: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005, 64:1468–1470.
Jarand J, Zochodne DW, Martin LO, Voll C: Neurological complications of infliximab. J Rheumatol 2006, 33:1018–1020.
Tektonidou MG, Serelis J, Skopouli FN: Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol 2007, 26:258–260.
Singer OC, Otto B, Steinmetz H, Ziemann U: Acute neuropathy with multiple conduction blocks after TNF monoclonal antibody therapy. Neurology 2004, 63:1754.
Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, et al.: Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology 2005, 44:132–133.
Birnbaum J: Infliximab-associated neuropathy in RA patients—the importance of considering the diagnosis of mononeuritis multiplex. Clin Rheumatol 2007, 26:281–282.
Carulli MT, Davies UM: Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology (Oxford) 2002, 41:952–953.
Bonnel RA, Graham DJ: Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004, 75:580–585.
Metzler C, Arlt AC, Gross WL, Brandt J: Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann Rheum Dis 2005, 64:1798–1800.
Bharadwaj A, Haroon N: Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 2004, 43:934.
Martin K, Bentaberry F, Dumoulin C, et al.: Neuropathy associated with leflunomide: a case series. Ann Rheum Dis 2005, 64:649–650.
Kho LK, Kermode AG: Leflunomide-induced peripheral neuropathy. J Clin Neurosci 2007, 14:179–181.
Richards BL, Spies J, McGill N, et al.: Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007, 37:101–107.
Martin K, Bentaberry F, Dumoulin C, et al.: Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol Drug Saf 2007, 16:74–78.
Jacobs MB: HMG-CoA reductase inhibitor therapy and peripheral neuropathy [letter]. Ann Intern Med 1994, 120:970.
Ahmad S: Lovastatin and peripheral neuropathy. Am Heart J 1995, 130:1321.
Phan T, McLeod JG, Pollard JD, et al.: Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995, 58:625–628.
Jeppesen U, Gaist D, Smith T, Sindrup SH: Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999, 54:835–838.
Lo YL, Leoh TH, Loh LM, Tan CE: Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci 2003, 208:105–108.
Walravens PA, Greene C, Seerman FE: Lovastatin, isoprenes, and myopathy. Lancet 1989, 2:1097–1098.
Gaist D, Jeppesen U, Andersen M, et al.: Statins and risk of polyneuropathy: a case-control study. Neurology 2002, 58:1333–1337.
Donaghy M: Assessing the risk of drug-induced neurologic disorders. Statins and neuropathy. Neurology 2002, 58:1321–1322.
Anderson JL, Muhlestein JB, Bair TL, et al.: Do statins increase the risk of idiopathic polyneuropathy? Am J Cardiol 2005, 95:1097–1099.
Davis TM, Yeap BB, Davis WA, Bruce DG: Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008, 51:562–566.
Ii M, Nishimura H, Kusano KF, et al.: Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005, 112:93–102.
Sarkey JP, Richards MP, Stubbs EB Jr: Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome. J Neurochem 2007, 100:1265–1277.
Spruijt L, Naviaux RK, McGowan KA, et al.: Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate. Muscle Nerve 2001, 24:916–924.
Kaufmann P, Engelstad K, Wei Y, et al.: Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006, 66:324–330.
Anselm IA, Darras BT: Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006, 67:1313.
Stacpoole PW, Gilbert LR, Neiberger RE, et al.: Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 2008, 121:e1223–e1228.
Felitsyn N, Stacpoole PW, Notterpek L: Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect. J Neurochem 2007, 100:429–436.
Felitsyn N, McLeod C, Shroads AL, et al.: The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem 2008, 106:2068–2079.
Heckmann JG, Dütsch M, Schwab S: Linezolid-associated small-fiber neuropathy. J Peripher Nerv Syst 2008, 13:157–158.
Chao CC, Sun HY, Chang YC, Hsieh ST: Painful neuropathy with skin denervation after prolonged use of linezolid. J Neurol Neurosurg Psychiatry 2008, 79:97–99.
Rho JP, Sia IG, Crum BA, et al.: Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004, 9:927–930.
Narita M, Tsuji BT, Yu VL: Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007, 27:1189–1197.
Rucker JC, Hamilton SR, Bardenstein D, et al.: Linezolid-associated toxic optic neuropathy. Neurology 2006, 66:595–598.
Zivkovic SA, Lacomis D: Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005, 64:926–927.
Centers for Disease Control and Prevention (CDC): Investigation of progressive inflammatory neuropathy among swine slaughterhouse workers—Minnesota, 2007–2008. MMWR Morb Mortal Wkly Rep 2008, 57:122–124.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weimer, L.H., Sachdev, N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 9, 69–75 (2009). https://doi.org/10.1007/s11910-009-0011-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-009-0011-z